Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H70O35 |
Molecular Weight | 1134.9842 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 35 / 35 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12O[C@H](CO)[C@@]([H])(O[C@@]3([H])O[C@H](CO)[C@@]([H])(O[C@@]4([H])O[C@H](CO)[C@@]([H])(O[C@@]5([H])O[C@H](CO)[C@@]([H])(O[C@@]6([H])O[C@H](CO)[C@@]([H])(O[C@@]7([H])O[C@H](CO)[C@@]([H])(O[C@@]8([H])O[C@H](CO)[C@@]([H])(O1)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O
InChI
InChIKey=WHGYBXFWUBPSRW-FOUAGVGXSA-N
InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28155026Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/27184436 | https://www.drugs.com/inactive/betadex-21.html | http://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_m8744.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28155026
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/27184436 | https://www.drugs.com/inactive/betadex-21.html | http://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_m8744.html
Betadex is a nonreducing cyclic compound composed of seven alpha-(1-4) linked D-glucopyranosyl units. It is a pharmacologically inactive substance. Betadex is useful for stabilizing, solubilizing or delivering intermediate size molecules. Cyclodextrins are cyclic oligosaccharides that have been used to modulate the composition of cholesterol and other lipids in biological membranes and have also been used as pharmaceutical excipients in the formulation of hydrophobic drugs. More recently, 2-Hydroxypropyl-β-cyclodextrins (HPβCDs) have gained attention as a potential therapeutic intervention for Niemann-Pick Disease Type C1 (NPC1) disease. HPβCDs are complex mixtures of different species, and variations in production may lead to differences in composition. 2-Hydroxypropyl-β-cyclodextrin dose-dependent effects against dysfunctional intracellular cholesterol trafficking in NPC1 cells.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0010879 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27184436 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient | Brexidol Approved UseBrexidol (piroxicam-beta-cyclodextrin) is a product indicated for the treatment of mild to severe acute pain. Launch Date1999 |
|||
Inactive ingredient | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02912793
15000, 2000 and 2500 mg/kg slow infusion for 8h every 2 weeks.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27184436
Treatment of Chinese hamster ovary cells with 2-hydroxypropyl-β-cyclodextrin induced a decrease in cell viability in a dosedependent manner. Significant cytotoxicity was observed in cells treated with ≥50 mM 2-hydroxypropyl-β-cyclodextrin.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-459
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
||
|
JECFA EVALUATION |
INS-459
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
||
|
NCI_THESAURUS |
C82130
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
||
|
DSLD |
300 (Number of products:2)
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6860
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
C80917
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL415690
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
269471
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
SUB05793MIG
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
100000086075
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
444041
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
2971
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
m3980
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
C031215
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
314334
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
DB03995
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
DTXSID1020358
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
JV039JZZ3A
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
231-493-2
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
1362685
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
74
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
JV039JZZ3A
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
1154569
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
495055
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY | |||
|
7585-39-9
Created by
admin on Fri Dec 15 15:46:05 GMT 2023 , Edited by admin on Fri Dec 15 15:46:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY